Phaseline

Targets › HCK

HCK (Tyrosine-protein kinase HCK): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jul 2028.

Non-receptor tyrosine-protein kinase found in hematopoietic cells that transmits signals from cell surface receptors and plays an important role in the regulation of innate immune responses, including neutrophil, monocyte, macrophage and mast cell functions, phagocytosis, cell survival and proliferation, cell adhesion and migration. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as…. (UniProt, P08631)

Open in Phaseline: the race on HCK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 2Chronic Myeloid LeukemiaNov 2028
Children's Oncology GroupBosutinib
Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor
ABL1, SRC, HCK, LYN, BCRPhase 1Philadelphia Chromosome Positive CMLJul 2028

Conditions

Chronic Myeloid Leukemia (1) Philadelphia Chromosome Positive CML (1)

Modalities

other (1), small molecule (1)

Companies

Baylor College of Medicine (1) Children's Oncology Group (1)

Related targets

ABL1 (2) SRC (2) LYN (2) BCR (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.